Loading
Breast trialist who co-led OlympiA, showing adjuvant olaparib improves survival in BRCA carriers.
Charles Geyer Jr. is a breast cancer trial leader with NRG Oncology and Professor of Medicine at the University of Pittsburgh. A medical oncologist and long-time NSABP/NRG leader, he co-chaired OlympiA, the trial of adjuvant olaparib in germline BRCA carriers, led NSABP B-31 analyses of adjuvant trastuzumab, and led the KATHERINE trial of trastuzumab emtansine for residual disease. His papers report the overall survival analysis of the OlympiA phase III trial in Annals of Oncology and trastuzumab emtansine for residual invasive HER2-positive breast cancer in the New England Journal of Medicine. His work covers triple-negative, HR-positive and HER2-positive breast cancer, PARP inhibitors and HER2.
| Title | Journal | Year |
|---|---|---|
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | Annals of Oncology | 2022 |
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | New England Journal of Medicine | 2019 |
| OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer | New England Journal of Medicine | 2021 |
The third trial to show carboplatin's benefit persists beyond pathological complete response and the trial that closed the neoadjuvant PARP inhibitor route in unselected triple-negative disease; PARP inhibition survives only in germline BRCA carriers.
The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
Shares Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA, Annals of Oncology, Olaparib.
Shares Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA, BRCA1 / BRCA2 (HRD).
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, HER2-positive breast cancer.
Shares Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, OlympiA, PARP.
Shares KATHERINE, KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Trastuzumab emtansine, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares OlympiA, Olaparib, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares OlympiA, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer.
Shares OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, PARP, Olaparib, BRCA1 / BRCA2 (HRD).